ResApp is a biotech company that commercialised technology to diagnose respiratory illnesses based on an audio recording of a patient’s cough on their phone. After proving immensely useful for diagnosing COVID-19 during the height of pandemic, Pfizer acquired the company for $180 million.
Throughout the episode, Tony discusses the path of listing on the ASX early-on and how that provided the initial capital needed for the company to succeed. Coming from a research background, Tony also talks about how his experience as a scholar and background in engineering contributes to being an effective CEO.
If you enjoy this episode, feel free to share with family and friends and leave a 5 star review.
Share the episode: https://thedionguagliardopodcast.buzzsprout.com/share
More on us!
Dion's Newsletter: http://eepurl.com/hHg1ff
Our social media: https://linktr.ee/FortressFinancial
Fortress Family Office: https://www.fortressfamilyoffice.com/
Contact us: admin@fortressfamilyoffice.com